Hepatic hemangioendothelioma of infancy: clinical features of a large cohort of patients and proposed management

Pediatr Surg Int. 2021 Jun;37(6):791-797. doi: 10.1007/s00383-021-04860-y. Epub 2021 Jan 29.

Abstract

Purpose: The management of hepatic hemangioendothelioma (HHE) may be challenging. We aimed to review a large cohort of children who presented to our centers with symptomatic HHE in the last 16 years.

Methods: We collected age at presentation, clinical features, histology, diagnostic process, management and outcome.

Results: Twenty seven patients (male/female 5/22), median age 13 days (1-1530) presented with hepatomegaly (24/27), cardiac failure (10/27), cutaneous hemangiomas (8/27), fever and anemia (6/27 each), vomiting (5/27), splenomegaly (4/27). The lesion was focal, multifocal, or diffuse in 9 patients of each group. The management included medical treatment (8/27), embolization (8/27), resection (3/27), observation (6/27), transplantation (2/27). After 16 months' follow-up (30 days-11 years), 23/27 (85%) were alive. Diffuse lesions (4/4), cardiac failure (4/4), type II histology (4/4), age older than 6 months at diagnosis (3/4) predicted mortality (all p < 0.01). Histology showed type 1 lesion in 3/8, type 2 in 3/8, and type 3 in 2/8 with foci of angiosarcoma.

Conclusion: Most patients with symptomatic HHE can be managed successfully with a combination of medical, radiological and surgical treatments. Patients with diffuse lesions, late presentation, cardiac failure and type II histology have a poor outcome.

Level of evidence: Diagnostic level IV. Therapeutic level IV.

Keywords: Angiosarcoma; Children; Hemangioendothelioma; Hemangioma; Liver; Tumor.

Publication types

  • Multicenter Study

MeSH terms

  • Embolization, Therapeutic / methods*
  • Female
  • Follow-Up Studies
  • Hemangioendothelioma / diagnosis*
  • Hemangioendothelioma / therapy
  • Humans
  • Infant
  • Male
  • Skin Neoplasms / diagnosis*
  • Skin Neoplasms / therapy
  • Time Factors